Loncastuximab Tesirine Shows Encouraging Results for the Treatment High-risk Follicular Lymphoma and Marginal Zone Lymphoma

Updated results from the two studies with loncastuximab tesirine ((Zynlonta® ADC Therapeutics), a CD19-directed antibody-drug conjugate (ADC). were presented during the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, held December 7 – 10, 2024, in San Diego, CA, and online. Both studies showed encouraging results in the treatment of patients diagnosed with high-risk forms of two blood cancers – follicular lymphoma (FL) and marginal zone lymphoma (MZL).

Authors

Publication Details

Journal
ADC Review / Journal of Antibody-drug Conjugates
Published
2024-12-13
DOI
https://doi.org/10.14229/jadc.2024.12.13.002
Primary Topic
Lymphoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Loncastuximab Tesirine Shows Encouraging Results for the Treatment High-risk Follicular Lymphoma and Marginal Zone Lymphoma

Danielle Garcia
ADC Review / Journal of Antibody-drug Conjugates
Lymphoma Diagnosis and Treatment
article

Loncastuximab Tesirine Shows Encouraging Results for the Treatment High-risk Follicular Lymphoma and Marginal Zone Lymphoma

Danielle Garcia
article en

Abstract

Updated results from the two studies with loncastuximab tesirine ((Zynlonta® ADC Therapeutics), a CD19-directed antibody-drug conjugate (ADC). were presented during the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, held December 7 – 10, 2024, in San Diego, CA, and online. Both studies showed encouraging results in the treatment of patients diagnosed with high-risk forms of two blood cancers – follicular lymphoma (FL) and marginal zone lymphoma (MZL).

ADC Review / Journal of Antibody-drug Conjugates
Good health and well-being
Openalex Percentile: Top 61%
Lymphoma Diagnosis and Treatment
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Loncastuximab Tesirine Shows Encouraging Results for the Treatment High-risk Follicular Lymphoma and Marginal Zone Lymphoma — Danielle Garcia · ADC Review / Journal of Antibody-drug Conjugates (2024) | TGRS Research Map | TGRS